Ppgl Pregnancy Imaging Selection

---
name: ppgl-pregnancy-imaging-selection
description: Selects safe imaging modalities for PPGL evaluation in pregnancy to minimize fetal radiation exposure, preferring ultrasound or MRI and reserving CT or 123I-MIBG scintigraphy for cases where diagnostic benefits outweigh radiation risks after informed consent. Triggered by phrases such as 'Pregnant patient with suspected PPGL symptoms,' 'Need imaging for PPGL in pregnant patient,' or 'Evaluating PPGL while minimizing fetal radiation risk.'
---

# Pregnancy-Specific PPGL Imaging Modality Selection

## STEP 1 — Gather Information
Collect gestational age, maternal symptoms (hypertension, palpitations, headache, sweating), biochemical test results (fractionated metanephrines, catecholamines, creatinine-corrected urine), prior imaging findings, and fetal viability status.

## STEP 2 — Rule In / Rule Out
If biochemical screening (fractionated metanephrines or catecholamines >3× upper limit) is negative, rule out PPGL and defer imaging; if positive, proceed to imaging evaluation.

## STEP 3 — Classify or Stratify
First-line imaging: ultrasound or MRI (both radiation-free). If initial US/MRI is nondiagnostic or further anatomic detail is required for surgical planning, classify as needing advanced imaging.

## STEP 4 — Decide
Perform US or MRI as initial study; if advanced imaging is deemed necessary after risk-benefit discussion, obtain informed consent and perform low-dose CT or 123I-MIBG scintigraphy with thyroid blockade (potassium iodide/Lugol’s solution).

## Clinical Guardrails / Mimics / Pitfalls
Do not use CT or 123I-MIBG as first-line without attempting US/MRI; avoid gadolinium-based contrast agents in MRI due to fetal safety concerns; never proceed with 123I-MIBG without thyroid blockade and documented informed consent regarding fetal radiation exposure.

## Concrete Clinical Example
A 28‑year‑old woman at 18 weeks gestation presents with episodic hypertension and palpitations; urinary metanephrines are 4× ULN. Abdominal ultrasound reveals a 1.5 cm left adrenal lesion; contrast‑free MRI confirms the lesion without metastasis. She is started on α‑blocker therapy and surgical resection is planned for the second trimester.

**Source:** Clinical Practice Guideline for the Diagnosis and Management of Pheochromocytoma and Paraganglioma, Japan Endocrine Society, 2025, doi:10.1507/endocrj.EJ25-0165